Recent clinical trial results have revealed that an obesity drug being developed by Novo Nordisk may allow for greater weight loss compared to the widely used obesity and type 2 diabetes drug terzipatide.
Hot Topics
About half of Libyans drink contaminated water What is the scientific reason?
Mauritania's blue treasure is in danger Will the map of fish in the Atlantic be redrawn?
The Citrus Secret Everyone's Talking About: Burn More, Crave Less & Feel Great Naturally
The advanced REIMAGINE 5 clinical trial showed that type 2 diabetes patients who received a weekly dose of 1 mg of CagriSema lost an average of 12.4% of their body weight over 60 weeks, compared to 9% in those who received a weekly dose of 5 mg of terzepate, the active ingredient in Mongaro and Zipbound. CagriSema also demonstrated improved blood sugar control in diabetic patients.
However, the comparison was limited to a 5 mg dose of terzepatide, whereas the dose can be increased to 10 mg or 15 mg, potentially leading to greater weight loss. In a separate phase 3 trial, overweight or obese adults lost approximately 21% of their body weight over 68 weeks when using Cagresima, compared to those who received a placebo.
Cagresima, administered via weekly injection, combines two active ingredients: semaglutide and cagrelintide. Semaglutide mimics the effects of the hormone GLP-1, which helps slow gastric emptying, increase satiety, and reduce appetite. Cagrelintide mimics the effects of the hormone amylin, which is involved in regulating appetite, satiety, and blood sugar levels. Semaglutide is also the active ingredient in Novo Nordisk's Ozempic and Wegovi medications.
Martin Holst Lange, Chief Scientific Officer of Novo Nordisk, said that the results of Cagresima were encouraging, noting that the combination of semaglutide and kagrilintide showed strong efficacy in weight loss and the treatment of obesity and type 2 diabetes.
Cagresima has not yet received approval from the U.S. Food and Drug Administration (FDA), but the company has submitted an application for approval, with a decision expected later this year. Novo Nordisk plans to launch the drug early next year, provided it receives the necessary regulatory approvals.
The most prominent side effects that appeared during the trials included gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal pain, which are also common with other GLP-1 drugs.
It is worth noting that Novo Nordisk is competing with other companies in the obesity drug market, most notably Eli Lilly, the producer of Mongaro and Zipbound, as demand increases for treatments that help with weight loss, appetite control, and blood sugar levels.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media
